Terms: = Bone cancer AND PSA AND Staging
268 results:
1. A pictorial view on false positive findings of
Dancheva Z; Chausheva S; Stoeva T; Dyankova M; Yordanova T; Chaushev B; Marinov R; Nikolov V; Abushev P; Todorov G; Dimitrova E; Klisarova A; Anakievski D
Hell J Nucl Med; 2024; 27(1):16-26. PubMed ID: 38629815
[TBL] [Abstract] [Full Text] [Related]
2. [
Li B; Ding X; Duan L; Shi J; Tang M; Zhang J; Zhao Z; Wu X; Gao Y
Front Endocrinol (Lausanne); 2024; 15():1326858. PubMed ID: 38449842
[TBL] [Abstract] [Full Text] [Related]
3. Ductal prostate cancer staging: Role of PSMA PET/CT.
Pepe P; Pepe L; Curduman M; Pennisi M; Fraggetta F
Arch Ital Urol Androl; 2024 Feb; 96(1):12132. PubMed ID: 38363231
[TBL] [Abstract] [Full Text] [Related]
4. Cost-Effectiveness Modeling of Prostate-Specific Membrane Antigen Positron Emission Tomography with Piflufolastat F 18 for the Initial Diagnosis of Patients with Prostate cancer in the United States.
Yee CW; Harvey MJ; Xin Y; Kirson NY
Pharmacoeconomics; 2024 Feb; 42(2):231-247. PubMed ID: 37934376
[TBL] [Abstract] [Full Text] [Related]
5. Comparing the role of 99m Tc-HYNIC-PSMA-11 and 99m Tc-MDP scintigraphy for the initial staging of intermediate to high-risk prostate cancer.
Ghaedian T; Abdinejad M; Nasrollahi H; Ghaedian M; Firuzyar T
Nucl Med Commun; 2023 Oct; 44(10):864-869. PubMed ID: 37464793
[TBL] [Abstract] [Full Text] [Related]
6. Targeted Biopsy in Men High Risk for Prostate cancer:
Pepe P; Pennisi M
Clin Genitourin Cancer; 2023 Dec; 21(6):639-642. PubMed ID: 37394379
[TBL] [Abstract] [Full Text] [Related]
7. PSMA hybrid imaging in prostate cancer - current applications and perspectives.
Koehler D; Berliner C; Shenas F; Karimzadeh A; Apostolova I; Klutmann S; Adam G; Sauer M
Rofo; 2023 Nov; 195(11):1001-1008. PubMed ID: 37348528
[TBL] [Abstract] [Full Text] [Related]
8. staging Prostate cancer with
Kesler M; Cohen D; Levine C; Sarid D; Keizman D; Yossepowitch O; Even-Sapir E
J Nucl Med; 2023 Jul; 64(7):1030-1035. PubMed ID: 37116912
[TBL] [Abstract] [Full Text] [Related]
9.
Pepe P; Pepe L; Tamburo M; Marletta G; Savoca F; Pennisi M; Fraggetta F
In Vivo; 2023; 37(3):1318-1322. PubMed ID: 37103095
[TBL] [Abstract] [Full Text] [Related]
10. Relationship between Proclarix and the Aggressiveness of Prostate cancer.
Campistol M; Triquell M; Regis L; Celma A; de Torres I; Semidey ME; Mast R; Mendez O; Planas J; Trilla E; Morote J
Mol Diagn Ther; 2023 Jul; 27(4):487-498. PubMed ID: 37081322
[TBL] [Abstract] [Full Text] [Related]
11. How PET-CT is Changing the Management of Non-metastatic Castration-resistant Prostate cancer?: Comment la TEP-TDM Peut Modifier la Prise en Charge du cancer de la Prostate Non Métastatique Résistant à la Castration ?
Baboudjian M; Gauthé M; Barret E; Brureau L; Rocchi P; Créhange G; Dariane C; Fiard G; Fromont G; Beauval JB; Mathieu R; Renard-Penna R; Roubaud G; Ruffion A; Sargos P; Rouprêt M; Ploussard G
Prog Urol; 2022 Jun; 32(6S1):6S43-6S53. PubMed ID: 36719646
[TBL] [Abstract] [Full Text] [Related]
12. Neoadjuvant radiohormonal therapy for oligo-metastatic prostate cancer: safety and efficacy outcomes from an open-label, dose-escalation, single-center, phase I/II clinical trial.
Chang Y; Zhao X; Xiao Y; Yan S; Xu W; Wang Y; Zhang H; Ren S
Front Med; 2023 Apr; 17(2):231-239. PubMed ID: 36580231
[TBL] [Abstract] [Full Text] [Related]
13. Oncologic outcomes of patients with lymph node invasion at prostatectomy and post-prostatectomy biochemical persistence.
Perera M; Lebdai S; Tin AL; Sjoberg DD; Benfante N; Beech BB; Alvim RG; Touijer AS; Jenjitranant P; Ehdaie B; Laudone VP; Eastham JA; Scardino PT; Touijer KA
Urol Oncol; 2023 Feb; 41(2):105.e19-105.e23. PubMed ID: 36435708
[TBL] [Abstract] [Full Text] [Related]
14. Role of
Sopeña Sutil R; Gómez Grande A; González Díaz A; Téigel Tobar J; Cabeza Rodríguez MÁ; González Billalabeitia E; Rodríguez Antolín A
Arch Esp Urol; 2022 Oct; 75(8):684-692. PubMed ID: 36330569
[TBL] [Abstract] [Full Text] [Related]
15. Prevalence of multimorbidity in men of African descent with and without prostate cancer in Soweto, South Africa.
Mapanga W; Norris SA; Craig A; Pumpalova Y; Ayeni OA; Chen WC; Jacobson JS; Neugut AI; Muchengeti M; Pentz A; Doherty S; Minkowitz S; Haffejee M; Rebbeck T; Joffe M
PLoS One; 2022; 17(10):e0276050. PubMed ID: 36256648
[TBL] [Abstract] [Full Text] [Related]
16. Safely omitting bone isotope scans in a cohort of grade group 2 prostate cancer.
Mustaffa A; Emara S
Prostate; 2023 Jan; 83(1):128-131. PubMed ID: 36176053
[TBL] [Abstract] [Full Text] [Related]
17. The clinical consequences of routine
Zacho HD; Nalliah S; Petersen A; Petersen LJ
Scand J Urol; 2022; 56(5-6):353-358. PubMed ID: 36073096
[TBL] [Abstract] [Full Text] [Related]
18. Characterization of bone metastases detected on
Önner H; Yılmaz F
Hell J Nucl Med; 2022; 25(1):57-62. PubMed ID: 35503556
[TBL] [Abstract] [Full Text] [Related]
19. Identification and Validation of the Prognostic Impact of Metastatic Prostate cancer Phenotypes.
Labe SA; Wang X; Lehrer EJ; Kishan AU; Spratt DE; Lin C; Morgans AK; Ponsky L; Garcia JA; Garrett S; Wang M; Zaorsky NG
Clin Genitourin Cancer; 2022 Aug; 20(4):371-380. PubMed ID: 35383004
[TBL] [Abstract] [Full Text] [Related]
20. staging
Kesler M; Kerzhner K; Druckmann I; Kuten J; Levine C; Sarid D; Keizman D; Yossepowitch O; Even-Sapir E
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):2077-2085. PubMed ID: 34957528
[TBL] [Abstract] [Full Text] [Related]
[Next]
